These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 39330048)
1. Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States. Moon HH; Kearney M; Mahmoudpour SH; Ike C; Morris V; Rava A; Kim S; Sun H; Boyd M; Gomez Rey G Curr Oncol; 2024 Sep; 31(9):5662-5676. PubMed ID: 39330048 [TBL] [Abstract][Full Text] [Related]
2. J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan. Kikuchi E; Hayakawa N; Nakayama M; Uno M; Nakatsu H; Kitagawa C; Miyake H; Yamada T; Fujita K; Shimoyama H; Nishihara K; Kobayashi M; Nakamura M; Fujimoto K; Sano T; Nishiyama N; Ito T; Kajita M; Kobayashi T; Kitamura H Int J Urol; 2024 Aug; 31(8):859-867. PubMed ID: 38722221 [TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Minato A; Furubayashi N; Tomoda T; Masaoka H; Song Y; Hori Y; Kiyoshima K; Negishi T; Kuroiwa K; Seki N; Tomisaki I; Nakamura M; Harada K; Fujimoto N Anticancer Res; 2024 Aug; 44(8):3419-3426. PubMed ID: 39060065 [TBL] [Abstract][Full Text] [Related]
4. A Podcast on Practical Considerations in Patients with Advanced Urothelial Cancer Receiving First-Line Cisplatin- or Carboplatin-Based Chemotherapy Followed by Avelumab Maintenance in a Changing Therapeutic Landscape. Gong J; Reimers MA Adv Ther; 2024 Sep; 41(9):3441-3451. PubMed ID: 39023740 [TBL] [Abstract][Full Text] [Related]
5. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Grivas P; Agarwal N; Pal S; Kalebasty AR; Sridhar SS; Smith J; Devgan G; Sternberg CN; Bellmunt J Cancer Treat Rev; 2021 Jun; 97():102187. PubMed ID: 33839438 [TBL] [Abstract][Full Text] [Related]
6. Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort. Miyake M; Nishimura N; Oda Y; Miyamoto T; Iida K; Inoue K; Tachibana A; Yoshikawa T; Sakamoto K; Ohnishi M; Maesaka F; Takamatsu N; Mieda K; Ohmori C; Matsubara T; Tomizawa M; Shimizu T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K; Int J Clin Oncol; 2024 Sep; 29(9):1311-1325. PubMed ID: 38888683 [TBL] [Abstract][Full Text] [Related]
7. Real-World Evidence of Tumor and Patient Characteristics and Survival with Avelumab Maintenance after Chemotherapy for Advanced and Metastatic Urothelial Carcinoma. Banek S; Wenzel M; Lauer B; Le QC; Hoeh B; Koll F; Cano Garcia C; Humke C; Köllermann J; Chun FKH; Kosiba M; Kluth LA Urol Int; 2024; 108(4):285-291. PubMed ID: 38447555 [TBL] [Abstract][Full Text] [Related]
8. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288 [TBL] [Abstract][Full Text] [Related]
9. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice. Grivas P; Grande E; Davis ID; Moon HH; Grimm MO; Gupta S; Barthélémy P; Thibault C; Guenther S; Hanson S; Sternberg CN ESMO Open; 2023 Dec; 8(6):102050. PubMed ID: 37976999 [TBL] [Abstract][Full Text] [Related]
10. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel. Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France. Porte F; Granghaud A; Chang J; Kearney M; Morel A; Plessala I; Cawston H; Roiz J; Xiao Y; Solbes MN; Lambert P; Ravaud A; Loriot Y; Thiery-Vuillemin A; Lévy P PLoS One; 2024; 19(5):e0302548. PubMed ID: 38728337 [TBL] [Abstract][Full Text] [Related]
12. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience. Bakaloudi DR; Talukder R; Lin GI; Makrakis D; Diamantopoulos LN; Tripathi N; Agarwal N; Zakopoulou R; Bamias A; Brown JR; Pinato DJ; Korolewicz J; Jindal T; Koshkin VS; Murgić J; Miletić M; Frobe A; Johnson J; Zakharia Y; Drakaki A; Rodriguez-Vida A; Rey-Cárdenas M; Castellano D; Buznego LA; Duran I; Carballeira CC; Barrera RM; Marmorejo D; McKay RR; Stewart T; Gupta S; Ruplin AT; Yu EY; Khaki AR; Grivas P Clin Genitourin Cancer; 2023 Oct; 21(5):584-593. PubMed ID: 37414620 [TBL] [Abstract][Full Text] [Related]
13. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulović S; Demey W; Ullén A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte R; Wang J; Huang B; Davis C; Fowst C; Costa N; Blake-Haskins JA; di Pietro A; Grivas P N Engl J Med; 2020 Sep; 383(13):1218-1230. PubMed ID: 32945632 [TBL] [Abstract][Full Text] [Related]
14. Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel. Bhanegaonkar A; Liu FX; Boyd M; Fulcher N; Kim R; Krulewicz S; Smith J; Cowey CL Oncologist; 2021 Sep; 26(9):e1633-e1643. PubMed ID: 34101298 [TBL] [Abstract][Full Text] [Related]
15. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis. Tomita Y; Yamamoto Y; Tsuchiya N; Kanayama H; Eto M; Miyake H; Powles T; Yoshida M; Koide Y; Umeyama Y; di Pietro A; Uemura H Int J Clin Oncol; 2022 Feb; 27(2):383-395. PubMed ID: 34973108 [TBL] [Abstract][Full Text] [Related]
16. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany. Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042 [No Abstract] [Full Text] [Related]
17. Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy. Morgans AK; Grewal S; Hepp Z; Fuldeore R; Odak S; Macahilig C; Shillington AC; Sonpavde G Clin Genitourin Cancer; 2022 Dec; 20(6):543-552. PubMed ID: 36088235 [TBL] [Abstract][Full Text] [Related]
18. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data. Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449 [TBL] [Abstract][Full Text] [Related]